Patents Assigned to Kagoshima University
-
Patent number: 11198106Abstract: An object of the invention is to provide a method for producing a capsule or microbead having high encapsulation efficiency of an encapsulated substance, high production efficiency, and high versatility. The invention relates to a method for producing a microcapsule or microbead, comprising: a step of disposing a monomer droplet or polymer droplet containing a substance to be encapsulated, which has a surface coated with a plurality of solid fine particles, on a flat surface; and a step of solidifying the monomer droplet or polymer droplet disposed on the flat surface in a gas phase so as to form an outer shell of a capsule or microbead, thereby forming a region enclosed by the outer shell, wherein the substance is encapsulated in the region.Type: GrantFiled: August 8, 2018Date of Patent: December 14, 2021Assignee: KAGOSHIMA UNIVERSITYInventors: Takayuki Takei, Masahiro Yoshida, Yoshihiro Ohzuno, Gen Hayase
-
Publication number: 20210380637Abstract: The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula: (in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).Type: ApplicationFiled: October 7, 2019Publication date: December 9, 2021Applicants: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji ITO, Seiichi UCHIMURA
-
Patent number: 11186613Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.Type: GrantFiled: November 17, 2017Date of Patent: November 30, 2021Assignees: Kagoshima University, Daicel CorporationInventors: Yuji Ito, Seiichi Uchimura
-
Publication number: 20210332152Abstract: An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.Type: ApplicationFiled: August 1, 2019Publication date: October 28, 2021Applicants: KAGOSHIMA UNIVERSITY, DAICEL CORPORATIONInventors: Yuji ITO, Seiichi UCHIMURA, Hiromichi OKURA
-
Patent number: 11117963Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.Type: GrantFiled: December 25, 2017Date of Patent: September 14, 2021Assignees: KYOWA HAKKO KIRIN CO., LTD., KAGOSHIMA UNIVERSITYInventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
-
Patent number: 11110414Abstract: A bubble generation device includes: a metallic narrow tube (10) through which water passes; and a pump that pressure-feeds the water containing a gas component into the metallic narrow tube (10). A drawer (11) in which a path through which the water passes is narrower than the front and the rear thereof in the flow direction of the water is disposed on the inside of the metallic narrow tube (10). The drawer (11) has the rectangular cross section orthogonal to the flow direction. The gas component contained in the water is dissolved in the water by pressure-feeding the water to the drawer (11), bubbles are evolved due to a decrease in pressure in the drawer (11), turbulent flow is generated in the water in the drawer (11) to crush bubbles in the water by the shearing force thereof, and bubbles are crushed by a shock wave caused by transonic flow occurring in the water that has exited from the drawer (11).Type: GrantFiled: July 21, 2017Date of Patent: September 7, 2021Assignee: Kagoshima UniversityInventor: Takashi Goshima
-
Publication number: 20210269548Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: ApplicationFiled: June 26, 2019Publication date: September 2, 2021Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITYInventors: Nobuaki TAKAHASHI, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO
-
Publication number: 20210188841Abstract: This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: September 27, 2018Publication date: June 24, 2021Applicants: KAGOSHIMA UNIVERSITY, SHOWA UNIVERSITYInventors: Takashi KURIHARA, Ichiro TAKASAKI, Naoki TOYOOKA, Hiroaki GOUDA
-
Publication number: 20210170058Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.Type: ApplicationFiled: April 15, 2019Publication date: June 10, 2021Applicants: NIHON MEDI-PHYSICS CO., LTD., National University Corporation Kagoshima University, National University Corporation Chiba UniversityInventors: Shota KOMOTO, Yu OGAWA, Yoshinari SHOYAMA, Tadashi HATANO, Yuji ITO, Yasushi ARANO, Hiroyuki SUZUKI, Tomoya UEHARA
-
Publication number: 20210147512Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.Type: ApplicationFiled: May 18, 2018Publication date: May 20, 2021Applicant: Kagoshima UniversityInventor: Yuji Ito
-
Publication number: 20210147541Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.Type: ApplicationFiled: June 26, 2019Publication date: May 20, 2021Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITYInventors: Nobuaki TAKAHASHI, Ryosuke NAKANO, Sayaka MAEDA, Takenao YAMADA, Yuji ITO
-
NOVEL APPLICATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FOR MEDICAL PURPOSES
Publication number: 20210138037Abstract: The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal.Type: ApplicationFiled: December 30, 2020Publication date: May 13, 2021Applicant: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro KOSAI, Cin Khai NGIN, Tomoyuki TAKAHASHI -
Patent number: 11001557Abstract: The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.Type: GrantFiled: January 16, 2018Date of Patent: May 11, 2021Assignees: Kagoshima University, Nobelpharma Co., Ltd.Inventors: Masanori Baba, Masaaki Toyama, Norikazu Sakakibara
-
Patent number: 10987372Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).Type: GrantFiled: March 10, 2017Date of Patent: April 27, 2021Assignees: KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, DAIKIN INDUSTRIES, LTD.Inventors: Masanori Ikeda, Midori Takeda, Masanori Baba, Nobuyuki Kato
-
Patent number: 10905742Abstract: The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal.Type: GrantFiled: September 28, 2006Date of Patent: February 2, 2021Assignee: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro Kosai, Cin Khai Ngin, Tomoyuki Takahashi
-
Publication number: 20210008134Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.Type: ApplicationFiled: November 8, 2018Publication date: January 14, 2021Applicant: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro KOSAI, Nobuhiro IJICHI
-
Patent number: 10882005Abstract: A hydrogen gas producing apparatus includes a porous body (100) and a mixed gas source (300). The porous body (100) is permeable to hydrogen gas and carbon dioxide gas, and has a property of being more permeable to hydrogen gas than carbon dioxide gas. The mixed gas source (300) causes a mixed gas including carbon dioxide gas and hydrogen gas to flow into the porous body (100) under a condition that a pressure gradient represented by (P1?P2)/L is below 50 MPa/m, where L represents the length of the porous body (100) in a direction in which the mixed gas permeates; P1 represents an inflow pressure of the mixed gas into the porous body (100); and P2 represents an outflow pressure thereof from the porous body (100).Type: GrantFiled: July 25, 2016Date of Patent: January 5, 2021Assignee: Kagoshima UniversityInventors: Yoshihiro Hirata, Taro Shimonosono, Hikari Imada
-
Patent number: 10772887Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.Type: GrantFiled: August 2, 2017Date of Patent: September 15, 2020Assignee: Kagoshima UniversityInventors: Daisuke Kodama, Shuji Izumo
-
Patent number: 10738324Abstract: Disclosed is a vector, preferably a viral vector, containing a treatment factor and/or a nucleic acid encoding a cytotoxic factor under control of an Aurora kinase promoter. Also disclosed is a virus vector in which the promoter of a nucleic acid encoding a factor necessary to the replication or assembly of at least one virus is substituted by the Aurora kinase promoter. Also disclosed are a disease treatment agent, in particular a cancer treatment agent, which contains the aforementioned vector, and a clinical diagnostic agent, in particular a cancer diagnostic agent, which contains the vector containing the Aurora kinase promoter.Type: GrantFiled: September 29, 2011Date of Patent: August 11, 2020Assignee: KAGOSHIMA UNIVERSITYInventor: Ken-ichiro Kosai
-
Publication number: 20200181196Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.Type: ApplicationFiled: June 12, 2017Publication date: June 11, 2020Applicant: Kagoshima UniversityInventors: Yuji ITO, Yoshinari SHOYAMA, Akio HAYASHI, Norihito NAKATA